206 related articles for article (PubMed ID: 18675868)
1. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
Borja-Cabrera GP; Santos FN; Bauer FS; Parra LE; Menz I; Morgado AA; Soares IS; Batista LM; Palatnik-de-Sousa CB
Vaccine; 2008 Sep; 26(39):4991-7. PubMed ID: 18675868
[TBL] [Abstract][Full Text] [Related]
2. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
Palatnik-de-Sousa CB; Barbosa Ade F; Oliveira SM; Nico D; Bernardo RR; Santos WR; Rodrigues MM; Soares I; Borja-Cabrera GP
Expert Rev Vaccines; 2008 Aug; 7(6):833-51. PubMed ID: 18665780
[TBL] [Abstract][Full Text] [Related]
3. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas.
Palatnik-de-Sousa CB; Silva-Antunes I; Morgado Ade A; Menz I; Palatnik M; Lavor C
Vaccine; 2009 Jun; 27(27):3505-12. PubMed ID: 19464528
[TBL] [Abstract][Full Text] [Related]
4. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
Parra LE; Borja-Cabrera GP; Santos FN; Souza LO; Palatnik-de-Sousa CB; Menz I
Vaccine; 2007 Mar; 25(12):2180-6. PubMed ID: 17239495
[TBL] [Abstract][Full Text] [Related]
5. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
[TBL] [Abstract][Full Text] [Related]
6. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
7. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis.
Fernandes CB; Junior JT; de Jesus C; Souza BM; Larangeira DF; Fraga DB; Tavares Veras PS; Barrouin-Melo SM
Vaccine; 2014 Mar; 32(11):1287-95. PubMed ID: 24406392
[TBL] [Abstract][Full Text] [Related]
9. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
[TBL] [Abstract][Full Text] [Related]
10. Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs.
Fiuza JA; Santiago Hda C; Selvapandiyan A; Gannavaram S; Ricci ND; Bueno LL; Bartholomeu DC; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2013 Apr; 31(14):1785-92. PubMed ID: 23398933
[TBL] [Abstract][Full Text] [Related]
11. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
12. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB
Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal analysis of serological tests officially adopted by the Brazilian Ministry of Health for the diagnosis of canine visceral leishmaniasis in dogs vaccinated with Leishmune®.
Marcondes M; de Lima VM; de Araújo Mde F; Hiramoto RM; Tolezano JE; Vieira RF; Biondo AW
Vet Parasitol; 2013 Nov; 197(3-4):649-52. PubMed ID: 23920056
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
[TBL] [Abstract][Full Text] [Related]
15. Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil.
Regina-Silva S; Feres AM; França-Silva JC; Dias ES; Michalsky ÉM; de Andrade HM; Coelho EA; Ribeiro GM; Fernandes AP; Machado-Coelho GL
Vaccine; 2016 Apr; 34(19):2233-9. PubMed ID: 26997002
[TBL] [Abstract][Full Text] [Related]
16. Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
Araújo MS; de Andrade RA; Sathler-Avelar R; Magalhães CP; Carvalho AT; Andrade MC; Campolina SS; Mello MN; Vianna LR; Mayrink W; Reis AB; Malaquias LC; Rocha LM; Martins-Filho OA
Vet Immunol Immunopathol; 2011 May; 141(1-2):64-75. PubMed ID: 21439654
[TBL] [Abstract][Full Text] [Related]
17. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).
Borja-Cabrera GP; Correia Pontes NN; da Silva VO; Paraguai de Souza E; Santos WR; Gomes EM; Luz KG; Palatnik M; Palatnik de Sousa CB
Vaccine; 2002 Sep; 20(27-28):3277-84. PubMed ID: 12213397
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside Hydrolase NH 36: A Vital Enzyme for the
Palatnik-de-Sousa CB
Front Immunol; 2019; 10():813. PubMed ID: 31040850
[TBL] [Abstract][Full Text] [Related]
20. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.
Roatt BM; Aguiar-Soares RD; Vitoriano-Souza J; Coura-Vital W; Braga SL; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; de Lana M; Figueiredo Gontijo N; Marques MJ; Giunchetti RC; Reis AB
PLoS One; 2012; 7(11):e49780. PubMed ID: 23189161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
